that dim automatically and fire protection products for the commercial building industry, will do well. “Gentex is a stable, high-quality industry leader, and it has shown an ability to maintain its margins and avoid pricing pressures, even in the face of new competition,” says Johnson.
Ron Johnson
Private Screening Picks
| Company Exchange: Symbol |
Price | 12-to 18-Month Price Target |
P/E on Projected 2004 Earnings |
Est. 5-Yr. Annual EPS ]Growth Rate |
Why Stock Will Outperform |
| American Express Co. (NYSE: AXP) |
$50.70 | $57.00 | 18.0 | 11.4% | American Express stands to grow by creatively and opportunely offering premium financial products to a target market. |
| Boston Scientific Corp. (NYSE: BSX) |
$44.30 | $54.00 | 21.9 | 30% | Boston Scientific will likely monopolize the U.S. and international markets with its coronary stent. |
| CVS Corp. (NYSE: CVS) |
$41.68 | $47.00 | 18.0 | 20% | CVS’ acquisition of 1,260 Eckerd drugstores, including its mail order and pharmacy benefits, should boost sales. |
| Target Corp. (NYSE: TGT) |
$44.70 | $49.00 | 18.5 | 16% | Target will benefit from its sale of underperforming retail divisions Mervyn’s and Marshall Field’s. |
| Gentex Corp. (NASDAQ: GNTX) |
$38.05 | $46.00 | 22.9 | 18% | Gentex is an industry leader and has proven it can maintain its margins and avoid pricing pressures. |
| SOURCE: SMITH, GRAHAM & CO., YAHOO! FINANCE; MORNINGSTAR.COM *AS OF MAY 28, 2004 | |||||